A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006846/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to evaluate the long-term safety of LDX administered
as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years
of age inclusive at the time of consent).
提供机构：
Vivli
创建时间：
2021-04-07
